In the release, the Japanese drugmaker said NTK’s claims that it interfered with the latter’s open offer are “without any ...

Merck KGaA has shown off data that fueled its $85 million bet on a late-phase treatment for a rare, locally aggressive tumor.

"Daiichi Sankyo and MSD announce first subject dosing in oesophageal cancer trial" was originally created and published by ...

The lawsuit, first announced on Nov 14, 2023, arose from alleged obstruction by the Japanese drug maker against NTK’s efforts ...

IHH Healthcare said on Tuesday its unit has filed a petition in a Tokyo court to revise damages sought from Japan's Daiichi ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

IHH Healthcare’s indirect subsidiary, NTK, has filed an application with the Tokyo District Court to increase its ongoing ...

IHH Healthcare's indirect subsidiary, Northern TK Venture Pte Ltd, has significantly increased its damages claim against ...

Malaysia's IHH Healthcare has significantly increased its damage claim against Japan's Daiichi Sankyo in Tokyo District Court ...

The global, randomized IDeate-Esophageal01 study will evaluate ifinatamab deruxtecan, a B7-H3–targeted antibody-drug ...

Malaysia's IHH Healthcare is seeking JPY 200 billion (Rs 11,800 crore) in damages from Japan's Daiichi Sankyo for blocking ...